Iovance Biotherapeutics Inc. (IOVA)
IOVA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/0001104659-26-018899-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | IOVA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001425205 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $263.5M |
| Net income | -$391.0M |
| Operating income | -$403.4M |
| Net margin | -148.4% |
| Operating margin | -153.1% |
| Revenue growth | +60.6% |
| Cash | $163.1M |
| Total assets | $913.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 13.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $57.9M cash; operating cash flow -$47.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 462,655,151 (2026-10-27); 396,967,970 a year earlier; 255,918,448 three years earlier. | Cover page 2026-10-27 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-06-18 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Mateo, California, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $121.5M | -$22.3M | -$4.5M | $57.9M | No debt tags | $379.0M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $99.3M | -$47.3M | -$60.8M | $110.8M | No debt tags | $325.0M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $71.4M | -$79.0M | -$72.1M | $196.5M | $1.0M | $285.6M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $86.8M | -$71.9M | -$52.6M | $163.1M | $1.0M | $263.5M | 10-K 2026-02-24 |
| Q3 2025 2025-09-30 | $67.5M | -$91.3M | -$78.7M | $158.1M | $1.0M | $250.4M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $60.0M | -$111.7M | -$67.4M | $132.5M | $1.0M | $241.5M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $49.3M | -$116.2M | -$103.7M | $171.7M | $1.0M | $212.7M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $73.7M | -$78.6M | -$73.3M | $115.7M | No debt tags | $164.1M | 10-K 2026-02-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-06-18 |
| Latest annual report | 10-K | 2026-02-24 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.5% |
| 1 month | -46.5% |
| 3 months | +19.0% |
| Year to date | +184.2% |
| 1 year | +222.0% |
| From 52-week high | -47.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RLAY | Relay Therapeutics Inc. | $17.27 | -4.53% | $3.8B |
| TARS | Tarsus Pharmaceuticals Inc. | $78.68 | -1.99% | $3.9B |
| CRSP | CRISPR Therapeutics AG Common Shares | $40.37 | -4.43% | $3.9B |
| ADMA | ADMA Biologics Inc | $13.47 | -1.54% | $3.0B |
| VCEL | Vericel Corporation | $57.48 | +0.91% | $2.9B |
| DNLI | Denali Therapeutics Inc. | $18.08 | -3.52% | $2.9B |
| ADPT | Adaptive Biotechnologies Corporation | $27.87 | -4.03% | $4.5B |
| SRRK | Scholar Rock Holding Corporation | $44.54 | +3.09% | $5.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier